BLUE · Insider Trading
bluebird bio, Inc. Common Stock
Every open-market purchase and sale reported by BLUE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-06-03 | Michael Cloonan | Director | D | −1,867 | — |
| 2025-06-03 | Mark Vachon | Director | MIXED | −2,497 | — |
| 2025-06-03 | John O Agwunobi | Director | MIXED | −2,568 | — |
| 2025-06-03 | Richard A. Paulson | Director | MIXED | −1,478 | — |
| 2025-06-03 | Najoh Tita-Reid | Director | MIXED | −2,408 | — |
| 2025-06-03 | O. James Sterling | Chief Financial Officer | MIXED | −5,000 | — |
| 2025-06-03 | Elisabeth Leiderman | Director | MIXED | −2,357 | — |
| 2025-06-03 | Nick Leschly | Director | MIXED | −24,095 | — |
| 2025-06-03 | Charlotte Jones-Burton | Director | MIXED | −2,173 | — |
| 2025-06-03 | Richard A Colvin | Chief Medical Officer | MIXED | −7,718 | — |
| 2025-06-03 | Andrew Obenshain | President and CEO | MIXED | −18,327 | — |
| 2025-06-03 | Thomas J Klima | See Remarks | MIXED | −7,878 | — |
| 2025-06-03 | Joseph Vittiglio | Chief Business & Legal Officer | MIXED | −4,268 | — |
| 2025-03-05 | Thomas J Klima | See Remarks | Sell | −500 | −$1.96K |
| 2025-03-05 | Andrew Obenshain | President and CEO | Sell | −921 | −$3.61K |
| 2025-03-05 | Richard A Colvin | Chief Medical Officer | Sell | −584 | −$2.29K |
| 2025-02-12 | Andrew Obenshain | President and CEO | A | +763 | — |
| 2025-02-05 | Joseph Vittiglio | Chief Business & Legal Officer | Sell | −238 | −$1.76K |
| 2025-02-05 | Richard A Colvin | Chief Medical Officer | Sell | −64 | −$473 |
| 2025-02-05 | Thomas J Klima | See Remarks | Sell | −122 | −$902 |
| 2025-02-05 | Andrew Obenshain | President and CEO | Sell | −86 | −$636 |
| 2025-01-08 | Andrew Obenshain | President and CEO | Sell | −140 | −$1.29K |
| 2025-01-08 | Richard A Colvin | Chief Medical Officer | Sell | −19 | −$176 |
| 2024-12-12 | Andrew Obenshain | President and CEO | Sell | −971 | −$405 |
| 2024-12-12 | Richard A Colvin | Chief Medical Officer | Sell | −2,824 | −$1.18K |
| 2024-11-08 | Mark Vachon | Director | A | +24,900 | — |
| 2024-11-08 | John O Agwunobi | Director | A | +24,900 | — |
| 2024-11-08 | Charlotte Jones-Burton | Director | A | +24,900 | — |
| 2024-11-08 | Najoh Tita-Reid | Director | A | +24,900 | — |
| 2024-11-08 | Nick Leschly | Director | A | +24,900 | — |
| 2024-11-08 | Elisabeth Leiderman | Director | A | +24,900 | — |
| 2024-11-08 | Richard A. Paulson | Director | A | +24,900 | — |
| 2024-10-02 | Joseph Vittiglio | Chief Business & Legal Officer | A | +50,000 | — |
| 2024-10-02 | O. James Sterling | Chief Financial Officer | A | +100,000 | — |
| 2024-10-02 | Richard A Colvin | Chief Medical Officer | A | +50,000 | — |
| 2024-10-02 | Thomas J Klima | See Remarks | MIXED | +48,994 | −$529 |
| 2024-10-02 | Andrew Obenshain | President and CEO | MIXED | +95,220 | −$18.27K |
| 2024-10-02 | Michael Cloonan | Director | A | +37,350 | — |
| 2024-07-03 | O. James Sterling | Chief Financial Officer | A | +300,000 deriv. | — |
| 2024-06-24 | Michael Cloonan | Director | A | +74,775 deriv. | — |
| 2024-06-04 | Thomas J Klima | See Remarks | Sell | −3,834 | −$3.73K |
| 2024-03-05 | Joseph Vittiglio | Chief Business & Legal Officer | A | +199,000 deriv. | — |
| 2024-03-05 | Christopher Krawtschuk | Chief Financial Officer | A | +199,000 deriv. | — |
| 2024-03-05 | Richard A Colvin | Chief Medical Officer | Sell | −6,770 | −$10.34K |
| 2024-03-05 | Andrew Obenshain | President and CEO | Sell | −6,095 | −$9.31K |
| 2024-03-05 | Thomas J Klima | See Remarks | Sell | −4,573 | −$6.99K |
| 2024-02-06 | Andrew Obenshain | President and CEO | Sell | −1,879 | −$1.70K |
| 2024-02-06 | Thomas J Klima | See Remarks | Sell | −2,714 | −$2.45K |
| 2024-02-06 | Joseph Vittiglio | Chief Business & Legal Officer | Sell | −5,217 | −$4.71K |
| 2024-01-09 | Andrew Obenshain | President and CEO | Sell | −3,162 | −$4.52K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Andrew Obenshain | President and CEO | 9,300 | $46.22K |
| Joseph Vittiglio | Chief Business & Legal Officer | 3,125 | $15.53K |
| Richard A Colvin | Chief Medical Officer | 2,500 | $12.43K |
| Richard A. Paulson | Director | 1,323 | $6.58K |
| Nick Leschly | Director | 1,245 | $6.19K |
| John O Agwunobi | Director | 1,245 | $6.19K |
| Najoh Tita-Reid | Director | 1,245 | $6.19K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BLUE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.